Home Ingredients GeniusPure® (High-Purity Alpha-GPC)
CognitiveAthletic Performance

GeniusPure® (High-Purity Alpha-GPC)

Evidence Level
Moderate
2 Clinical Trials
3 Documented Benefits
3/5 Evidence Score

GeniusPure® (NNB Nutrition) is a patent-pending stabilized alpha-GPC (alpha-glycerylphosphorylcholine) at 70% or 90% concentration, solving the same hygroscopicity and stability problem that limited previous alpha-GPC supplements (standard 50% alpha-GPC bound to silica). Alpha-GPC is a well-absorbed form of choline that crosses the blood-brain barrier and serves as a direct precursor for acetylcholine synthesis. Most published alpha-GPC trials were run in older patients with dementia or stroke, and in countries including Italy, South Korea and Russia alpha-GPC is sold as a prescription medicine rather than a supplement, so those results are not a promise of benefit in healthy people. One acute trial in 20 healthy trained men did test GeniusPure itself. Read the safety section before considering long-term daily use.

Studied Dose Healthy adults: 315 mg or 630 mg as a single dose in the GeniusPure trial, or 600 mg/day for six days. Alzheimer's trials used 1,200 mg/day, a medical rather than general supplement dose.
Active Compound Alpha-glycerylphosphorylcholine (alpha-GPC), 70% or 90% concentration.

Benefits

Memory, learning, and cognitive enhancement

Alpha-GPC is one of the better studied choline donors. In healthy adults the direct evidence is thin: the one trial run on GeniusPure itself, a single-dose crossover in 20 resistance-trained men, improved Stroop test scores, and Stroop completion time at the higher dose, but showed no significant difference on the N-back memory task or the Flanker attention task. The patient evidence is stronger: a 180-day trial gave 1,200 mg/day to 261 people diagnosed with mild to moderate Alzheimer's disease and improved their ADAS-Cog and MMSE scores against placebo. That is evidence in patients under medical care, not evidence that a supplement treats or prevents dementia, and no cited trial compared alpha-GPC head to head against a cholinesterase inhibitor.

Supported by Trial 1, Trial 2

Neuromuscular performance and power output

The strongest published result here is small: 13 college-aged men taking 600 mg/day of alpha-GPC for six days produced more peak force in a lower-body isometric pull than on placebo (p = 0.044), while the upper-body test showed no significant difference (p = 0.127). The often-quoted 14 percent peak force and growth hormone figures come from a seven-man conference poster (Ziegenfuss 2008) that was never published as a full peer-reviewed paper. The trial run on GeniusPure itself measured vertical jump, bench press throws and growth hormone and found no difference from placebo.

Supported by Trial 2

Neuroprotection and long-term brain health

Alpha-GPC supplementation supports phosphatidylcholine synthesis in neuronal membranes, which helps maintain membrane fluidity, synaptic plasticity, and myelination essential for long-term cognitive health. The longer-term human data come from patients, not healthy users: in the ASCOMALVA trial, people already diagnosed with Alzheimer's disease plus ischemic brain damage who took choline alphoscerate alongside the prescription drug donepezil held their cognitive and daily-function scores better over 12 months than those on donepezil alone. Nothing cited here shows alpha-GPC prevents dementia or lowers dementia risk in healthy people.

Supported by Trial 1, Trial 2

Mechanism of action

1

Blood-brain barrier choline delivery and acetylcholine synthesis

Alpha-GPC crosses the blood-brain barrier via specific choline transporters and releases free choline into brain tissue, though direct head-to-head human comparisons against choline bitartrate or citicoline are limited. This choline is taken up by cholinergic neurons and converted by choline acetyltransferase (ChAT) to acetylcholine, the neurotransmitter governing memory consolidation, attention, and neuromuscular contraction. Alpha-GPC is a direct dietary precursor for brain acetylcholine synthesis.

Clinical trials

1
Alpha-GPC in Alzheimer's Disease Patients: Multi-Center RCT
PubMed

Multi-center, randomized, double-blind, placebo-controlled trial of alpha-GPC (1,200 mg/day) in 261 Alzheimer's patients with mild-to-moderate dementia for 180 days. Outcomes: MMSE, ADAS-Cog, Global Deterioration Scale, Clinical Global Impression. (De Jesus Moreno Moreno 2003, Clin Ther)

261 Alzheimer's disease patients. 180-day intervention.

Alpha-GPC produced significant improvements in MMSE, ADAS-Cog, and Global Deterioration Scale vs placebo at 90 and 180 days. Generally well-tolerated. Critical context: this 2003 trial was conducted in mild-moderate AD; subsequent more rigorous trials and modern AD treatment landscape (cholinesterase inhibitors, recently lecanemab/donanemab) make alpha-GPC a complementary consideration at best — not established AD treatment.

2
Alpha-GPC and Isometric Strength: Six-Day Crossover RCT

Randomized, double-blind, placebo-controlled crossover study of 600 mg/day alpha-GPC taken for six days, testing lower-body isometric mid-thigh pull and an upper-body isometric strength test. Growth hormone and cognition were not measured. Funded by an alpha-GPC ingredient supplier. (Bellar, LeBlanc and Campbell 2015, J Int Soc Sports Nutr 12:42)

13 college-aged men. Six days of supplementation, crossover design.

In 13 college-aged men, lower-body peak force improved more on alpha-GPC than on placebo (98.8 N vs -39.0 N change, p = 0.044), while the upper-body test did not reach significance (p = 0.127). The often-quoted 14 percent peak force figure and the large growth hormone rise come from a separate seven-man conference poster (Ziegenfuss 2008) that has never appeared as a full peer-reviewed paper. Note: small sample, single trial, industry funded; effects on real-world strength or hypertrophy outcomes are not established. Practical implication: alpha-GPC has emerging acute pre-exercise applications, distinct from its older Alzheimer's evidence.

Side effects and drug interactions

Common Potential side effects

Stroke signal worth knowing before long-term use: a South Korean national health insurance analysis of about 12 million adults aged 50 and over, followed for 10 years, found that people prescribed alpha-GPC had a stroke rate about 43 percent higher than matched non-users (adjusted hazard ratio 1.43, 95% CI 1.41 to 1.46), and the rate rose with longer prescription duration (Lee 2021, JAMA Network Open). This is observational data on people receiving a prescription drug, so it does not prove alpha-GPC causes stroke, and in South Korea alpha-GPC is often prescribed precisely for early cognitive or vascular complaints, which can inflate the association. It has not been ruled out either. Short trials report alpha-GPC is generally well tolerated
Headache in some users (cholinergic excess); reduce dose or add choline balance nutrients
Mild GI effects (nausea) at doses above 1,200 mg/day
Gut bacteria convert some choline to trimethylamine, which the liver turns into TMAO. Blood TMAO has been linked in observational research to higher cardiovascular and stroke risk, and it is the mechanism proposed for the stroke signal above, so this is more than a cosmetic issue. It can also cause a fishy body odor, which is rare and less common than with choline bitartrate

Important Drug interactions

Scopolamine and anticholinergic drugs: alpha-GPC opposes anticholinergic effects; reduced drug efficacy
Cholinesterase inhibitors (donepezil, rivastigmine): additive cholinergic effect; potential over-stimulation; consult physician
Regulatory status: alpha-GPC (choline alphoscerate) is sold as a prescription medicine for cognitive disorders in countries including Italy, South Korea and Russia, and is not FDA-approved to treat any disease. In the United States it is sold as a dietary supplement. No significant pharmacokinetic drug interactions have been reported at supplemental doses

More Cognitive Ingredients

Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an adaptogenic herb from Ayurvedic tradition, widely u…
Cognitive
Vitamin B6 (Pyridoxine)
Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, ne…
Cognitive
Bacopa Monnieri
Bacopa monnieri (Brahmi) is a cornerstone herb in Ayurvedic medicine with over 3,000 years…

Explore Other Ingredients

Cognitive
Citicoline
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine bios…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…
Cognitive
PQQ (Pyrroloquinoline Quinone)
Pyrroloquinoline quinone (PQQ) is a redox-active coenzyme that behaves as an antioxidant i…

Frequently asked questions about GeniusPure® (High-Purity Alpha-GPC)

What is GeniusPure?

GeniusPure® (NNB Nutrition) is a patent-pending stabilized alpha-GPC (alpha-glycerylphosphorylcholine) at 70% or 90% concentration, solving the same hygroscopicity and stability problem that limited previous alpha-GPC supplements (standard 50% alpha-GPC bound to silica).

What is GeniusPure used for?

GeniusPure is researched primarily for Cognitive and Athletic Performance. Alpha-GPC is one of the better studied choline donors. In healthy adults the direct evidence is thin: the one trial run on GeniusPure itself, a single-dose crossover in 20 resistance-trained men, improved Stroop test scores, and Stroop comp…

What is the recommended dosage of GeniusPure?

The clinically studied dose is Healthy adults: 315 mg or 630 mg as a single dose in the GeniusPure trial, or 600 mg/day for six days. Alzheimer's trials used 1,200 mg/day, a medical rather than general supplement dose. Always follow the product label and check with a healthcare provider for personal advice.

Is GeniusPure safe, and does it have side effects?

For most healthy adults, GeniusPure is well tolerated at studied doses. Reported effects can include: Stroke signal worth knowing before long-term use: a South Korean national health insurance analysis of about 12 million adults aged 50 and over, followed for 10 years, found that people prescribed alpha-GPC had a stroke rate about 43 percent higher than matched non-users (adjuste… It may also interact with some medications. GeniusPure is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does GeniusPure interact with any medications?

Possible interactions include: Scopolamine and anticholinergic drugs: alpha-GPC opposes anticholinergic effects; reduced drug efficacy Cholinesterase inhibitors (donepezil, rivastigmine): additive cholinergic effect; potential over-stimulation; consult physician If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for GeniusPure?

NutraSmarts rates the evidence for GeniusPure as Moderate (3 out of 5). It is backed by 2 clinical trials and 8 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(8 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kerksick CM Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men Nutrients. 2024;16(23):4240. doi: 10.3390/nu16234240.PubMedUsed to support: Backs the acute cognition claim only: a single 315 mg or 630 mg dose improved Stroop test score, with faster Stroop completion time at the 630 mg dose, in healthy resistance-trained men. Honesty: this trial did use GeniusPure (NNB Nutrition), which NNB Nutrition sponsored and on which the author serves as a paid scientific advisor. It is a single acute crossover in 20 healthy trained men, and only the Stroop test improved; N-back and Flanker did not. It also measured vertical jump, bench press throws and growth hormone and found no difference from placebo. The 14 percent peak force figure quoted elsewhere for alpha-GPC comes from a seven-man conference poster, not from this trial.
  2. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results J Neurol Sci. 2012;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003.PubMedUsed to support: Backs the cognitive-decline claim: adding choline alphoscerate (alpha-GPC) to donepezil better preserved cognition and function than donepezil alone in Alzheimer's with vascular injury. Honesty: 12-month interim results in 91 of a planned 210 patients, every one diagnosed with Alzheimer's disease plus neuroimaging-documented ischemic brain damage, and every one taking the prescription drug donepezil. Both arms received donepezil, so this measures what alpha-GPC adds to drug therapy in patients, not what it does for a healthy person. Generic alpha-GPC, not GeniusPure.
  3. Parnetti L, Amenta F, Gallai V Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data Mech Ageing Dev. 2001;122(16):2041-55. doi: 10.1016/s0047-6374(01)00312-8.PubMedUsed to support: Supports the cognition-in-decline claim by summarizing older controlled trials of alpha-GPC in dementia and post-stroke cognitive recovery. Honesty: it pools 13 trials in 4,054 patients, all of them people with dementia, TIA or stroke rather than healthy users, and the three stroke and TIA trials covering 2,484 of those patients were uncontrolled. The review itself describes choline alphoscerate as a centrally acting parasympathomimetic drug. It dates from 2001 and is not specific to GeniusPure.
  4. Che X, Zhao Y, Xu Z, Hu Y, Ren A, Wu C, Yang J Unlocking the Potential of L-alpha-Glycerylphosphorylcholine: From Metabolic Pathways to Therapeutic Applications Nutr Rev. 2025;83(8):1594-1620. doi: 10.1093/nutrit/nuaf008.PubMedUsed to support: Provides balanced context on alpha-GPC's mechanisms and benefits and its safety signal. Honesty: this review states that possible risks of atherosclerosis and stroke still await validation, a signal traced to the TMAO pathway and to a South Korean cohort of about 12 million adults in which alpha-GPC users had roughly 43 percent higher stroke risk over 10 years (Lee 2021, PMID 34817582); it is a review, not a GeniusPure efficacy trial.
  5. Lee G, Choi S, Chang J, et al. Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Netw Open. 2021;4(11):e2136008..PubMedUsed to support: Population-based retrospective cohort of 12,008,977 South Korean adults aged 50 and over with no history of stroke or Alzheimer disease, using National Health Insurance Service prescription records from 2006 to 2008 with follow-up from 1 January 2009 to 31 January 2018. Adjusted hazard ratio for total stroke among alpha-GPC users after covariate matching was 1.43 (95% CI 1.41 to 1.46), with 1.34 for ischemic and 1.37 for hemorrhagic stroke, and a dose-response gradient across prescription-duration categories. This is the actual source of the stroke signal the page previously gestured at inside a reference annotation. It is observational and subject to confounding by indication, because Korean insurance reimburses alpha-GPC for cognitive and cerebrovascular complaints, so it cannot show causation. It belongs on the safety section.
  6. Bellar D, LeBlanc NR, Campbell B The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr. 2015;12:42..PubMedUsed to support: Randomized, double-blind, placebo-controlled crossover trial in 13 college-aged males, 600 mg/day oral alpha-GPC for six days with a one-week washout. Lower-body isometric mid-thigh pull peak force change favored alpha-GPC (98.8 N vs -39.0 N, p = 0.044); the upper-body isometric test did not reach significance (p = 0.127). Growth hormone and cognition were not measured. Funded by Chemi Nutra, an alpha-GPC ingredient supplier, and the product was not GeniusPure. This is the peer-reviewed, PubMed-indexed trial that anchors the Athletic Performance category, and it is the trial the page's second clinical trial card was already describing incorrectly.
  7. De Jesus Moreno Moreno M Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-93..PubMedUsed to support: 261 patients with mild to moderate Alzheimer's disease (132 choline alfoscerate, 129 placebo), oral 400 mg capsules three times daily for 180 days; ADAS-Cog fell 2.42 points at 90 days and 3.20 points at 180 days from baseline while placebo worsened. This is the trial the page's first clinical trial card describes by name, and the card's link previously pointed to the wrong record (PMID 8477148, Parnetti 1993, Drugs Aging, alpha-GPC versus ST200 acetyl-L-carnitine). It is a disease-population trial and must be labelled as such wherever it is used.
  8. Sagaro GG, Amenta F Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Front Neurol. 2025;16:1649661..PubMedUsed to support: Meta-analysis of 3 randomized trials totalling 358 patients with dementia disorders, comparing choline alphoscerate head to head against citicoline. Choline alphoscerate was better on the Sandoz Clinical Assessment Geriatric scale (weighted mean difference -3.92, 95% CI -7.41 to -0.42) and on clinician-rated domains including cognitive function, interpersonal relationships, affective disorders, apathy and somatic functioning, but there was no significant difference between the two on memory or word fluency, and no significant difference in dropout. It is the newest synthesis in this field and it is the only head-to-head evidence bearing on the page's citicoline superlatives, and what it shows is a global-rating advantage in patients with no memory advantage, which is a narrower result than the sweeping bioavailability and validation claims this page used to make. It is small, entirely in dementia patients, and its senior author is Francesco Amenta, the ASCOMALVA principal investigator and a co-author of the 2001 pooled analysis already cited here, so it is not independent of the other evidence on this page.